11.33 USD
-0.19 (-1.65%)
11.33 USD
0 (0%)
Taking everything into account, VREX scores 5 out of 10 in our fundamental rating. VREX was compared to 188 industry peers in the Health Care Equipment & Supplies industry. VREX has only an average score on both its financial health and profitability. VREX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
VREX had positive earnings in the past year.
In the past year VREX had a positive cash flow from operations.
In multiple years VREX reported negative net income over the last 5 years.
VREX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -6.35%, VREX is in the better half of the industry, outperforming 64.89% of the companies in the same industry.
VREX has a Return On Equity of -14.88%. This is in the better half of the industry: VREX outperforms 63.30% of its industry peers.
VREX's Return On Invested Capital of 5.67% is fine compared to the rest of the industry. VREX outperforms 78.72% of its industry peers.
VREX had an Average Return On Invested Capital over the past 3 years of 4.82%. This is below the industry average of 8.78%.
The 3 year average ROIC (4.82%) for VREX is below the current ROIC(5.67%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.35% | ||
| ROE | -14.88% | ||
| ROIC | 5.67% |
ROA(3y)-2.14%
ROA(5y)-0.47%
ROE(3y)-5.1%
ROE(5y)-1.2%
ROIC(3y)4.82%
ROIC(5y)5.54%
1.3 Margins
VREX's Operating Margin of 7.83% is fine compared to the rest of the industry. VREX outperforms 74.47% of its industry peers.
VREX's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 34.40%, VREX is not doing good in the industry: 73.94% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of VREX has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.83% | ||
| PM (TTM) | N/A | ||
| GM | 34.4% |
OM growth 3Y-8.19%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y5.76%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so VREX is destroying value.
Compared to 1 year ago, VREX has more shares outstanding
Compared to 5 years ago, VREX has more shares outstanding
The debt/assets ratio for VREX has been reduced compared to a year ago.
2.2 Solvency
VREX has an Altman-Z score of 1.90. This is not the best score and indicates that VREX is in the grey zone with still only limited risk for bankruptcy at the moment.
VREX has a Altman-Z score of 1.90. This is in the better half of the industry: VREX outperforms 60.11% of its industry peers.
VREX has a debt to FCF ratio of 19.87. This is a negative value and a sign of low solvency as VREX would need 19.87 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 19.87, VREX is doing good in the industry, outperforming 70.21% of the companies in the same industry.
VREX has a Debt/Equity ratio of 0.79. This is a neutral value indicating VREX is somewhat dependend on debt financing.
VREX's Debt to Equity ratio of 0.79 is on the low side compared to the rest of the industry. VREX is outperformed by 70.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 19.87 | ||
| Altman-Z | 1.9 |
ROIC/WACC0.76
WACC7.46%
2.3 Liquidity
A Current Ratio of 3.43 indicates that VREX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.43, VREX is in the better half of the industry, outperforming 62.77% of the companies in the same industry.
A Quick Ratio of 1.83 indicates that VREX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.83, VREX is in line with its industry, outperforming 46.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.43 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
VREX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.00%, which is quite impressive.
The Earnings Per Share has been growing by 57.78% on average over the past years. This is a very strong growth
VREX shows a small growth in Revenue. In the last year, the Revenue has grown by 4.14%.
VREX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.73% yearly.
EPS 1Y (TTM)60%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%94.74%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y-0.58%
Revenue growth 5Y2.73%
Sales Q2Q%11.28%
3.2 Future
The Earnings Per Share is expected to grow by 8.20% on average over the next years. This is quite good.
VREX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.86% yearly.
EPS Next Y-6.84%
EPS Next 2Y8.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.97%
Revenue Next 2Y3.86%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 12.88, VREX is valued correctly.
VREX's Price/Earnings ratio is rather cheap when compared to the industry. VREX is cheaper than 89.89% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.15, VREX is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 13.82, the valuation of VREX can be described as correct.
Based on the Price/Forward Earnings ratio, VREX is valued cheaply inside the industry as 88.30% of the companies are valued more expensively.
VREX is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.22, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.88 | ||
| Fwd PE | 13.82 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VREX indicates a rather cheap valuation: VREX is cheaper than 95.74% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, VREX is valued cheaply inside the industry as 82.98% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.13 | ||
| EV/EBITDA | 7.38 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.22
EPS Next 2Y8.2%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for VREX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
11.33
-0.19 (-1.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.29%
Inst Owner Change2.62%
Ins Owners1.66%
Ins Owner Change-1.28%
Market Cap472.46M
Revenue(TTM)844.60M
Net Income(TTM)-70.30M
Analysts83.64
Price Target18.16 (60.28%)
Short Float %2.04%
Short Ratio2.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)251.48%
Min EPS beat(2)98.76%
Max EPS beat(2)404.2%
EPS beat(4)4
Avg EPS beat(4)167.83%
Min EPS beat(4)81.21%
Max EPS beat(4)404.2%
EPS beat(8)5
Avg EPS beat(8)85.78%
EPS beat(12)9
Avg EPS beat(12)64.21%
EPS beat(16)12
Avg EPS beat(16)54.96%
Revenue beat(2)2
Avg Revenue beat(2)3.46%
Min Revenue beat(2)2.35%
Max Revenue beat(2)4.57%
Revenue beat(4)3
Avg Revenue beat(4)1.33%
Min Revenue beat(4)-3.1%
Max Revenue beat(4)4.57%
Revenue beat(8)4
Avg Revenue beat(8)0.25%
Revenue beat(12)5
Avg Revenue beat(12)-0.02%
Revenue beat(16)8
Avg Revenue beat(16)-0.05%
PT rev (1m)2.3%
PT rev (3m)2.3%
EPS NQ rev (1m)-2.44%
EPS NQ rev (3m)-8.05%
EPS NY rev (1m)0%
EPS NY rev (3m)1.42%
Revenue NQ rev (1m)0.72%
Revenue NQ rev (3m)0.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.88 | ||
| Fwd PE | 13.82 | ||
| P/S | 0.56 | ||
| P/FCF | 25.13 | ||
| P/OCF | 11.33 | ||
| P/B | 1 | ||
| P/tB | 1.82 | ||
| EV/EBITDA | 7.38 |
EPS(TTM)0.88
EY7.77%
EPS(NY)0.82
Fwd EY7.24%
FCF(TTM)0.45
FCFY3.98%
OCF(TTM)1
OCFY8.83%
SpS20.25
BVpS11.33
TBVpS6.24
PEG (NY)N/A
PEG (5Y)0.22
Graham Number14.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.35% | ||
| ROE | -14.88% | ||
| ROCE | 7.18% | ||
| ROIC | 5.67% | ||
| ROICexc | 6.83% | ||
| ROICexgc | 9.45% | ||
| OM | 7.83% | ||
| PM (TTM) | N/A | ||
| GM | 34.4% | ||
| FCFM | 2.23% |
ROA(3y)-2.14%
ROA(5y)-0.47%
ROE(3y)-5.1%
ROE(5y)-1.2%
ROIC(3y)4.82%
ROIC(5y)5.54%
ROICexc(3y)5.86%
ROICexc(5y)6.54%
ROICexgc(3y)8.71%
ROICexgc(5y)10.09%
ROCE(3y)6.1%
ROCE(5y)7.01%
ROICexgc growth 3Y-6.75%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.38%
ROICexc growth 5YN/A
OM growth 3Y-8.19%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y5.76%
F-Score5
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 19.87 | ||
| Debt/EBITDA | 3.98 | ||
| Cap/Depr | 84.19% | ||
| Cap/Sales | 2.71% | ||
| Interest Coverage | 2.11 | ||
| Cash Conversion | 44.69% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.43 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 1.9 |
F-Score5
WACC7.46%
ROIC/WACC0.76
Cap/Depr(3y)77.68%
Cap/Depr(5y)67.38%
Cap/Sales(3y)2.78%
Cap/Sales(5y)2.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%94.74%
EPS Next Y-6.84%
EPS Next 2Y8.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.14%
Revenue growth 3Y-0.58%
Revenue growth 5Y2.73%
Sales Q2Q%11.28%
Revenue Next Year2.97%
Revenue Next 2Y3.86%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y105.28%
EBIT growth 3Y-8.72%
EBIT growth 5YN/A
EBIT Next Year53.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-7.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.84%
OCF growth 3Y35.13%
OCF growth 5Y25.87%
VAREX IMAGING CORP / VREX FAQ
What is the fundamental rating for VREX stock?
ChartMill assigns a fundamental rating of 5 / 10 to VREX.
Can you provide the valuation status for VAREX IMAGING CORP?
ChartMill assigns a valuation rating of 6 / 10 to VAREX IMAGING CORP (VREX). This can be considered as Fairly Valued.
What is the profitability of VREX stock?
VAREX IMAGING CORP (VREX) has a profitability rating of 5 / 10.
Can you provide the financial health for VREX stock?
The financial health rating of VAREX IMAGING CORP (VREX) is 5 / 10.
What is the earnings growth outlook for VAREX IMAGING CORP?
The Earnings per Share (EPS) of VAREX IMAGING CORP (VREX) is expected to decline by -6.84% in the next year.